ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

CNSP CNS Pharmaceuticals Inc

0.2099
0.0004 (0.19%)
After Hours
Last Updated: 18:05:24
Delayed by 15 minutes

Period:

Draw Mode:

Volume 506,502
Bid Price 0.203
Ask Price 0.2099
News -
Day High 0.219

Low
0.19

52 Week Range

High
2.98

Day Low 0.1971
Company Name Stock Ticker Symbol Market Type
CNS Pharmaceuticals Inc CNSP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0004 0.19% 0.2099 18:05:24
Open Price Low Price High Price Close Price Prev Close
0.205 0.1971 0.219 0.2049 0.2095
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
865 506,502 $ 0.2079426 $ 105,323 - 0.19 - 2.98
Last Trade Time Type Quantity Stock Price Currency
17:46:30 1 $ 0.21 USD

CNS Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.05M 5.25M - 0 -18.85M -3.59 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

CNS Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CNSP Message Board. Create One! See More Posts on CNSP Message Board See More Message Board Posts

Historical CNSP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.2190.320.19710.20969141,314,682-0.0091-4.16%
1 Month0.220.320.190.218637617,613-0.0101-4.59%
3 Months0.3880.4780.190.2623547343,092-0.1781-45.90%
6 Months2.252.31990.190.3727503352,413-2.04-90.67%
1 Year1.842.980.191.05289,143-1.63-88.59%
3 Years55.2080.400.1910.67695,397-54.99-99.62%
5 Years123.30170.6970.1931.68643,320-123.09-99.83%

CNS Pharmaceuticals Description

CNS Pharmaceuticals Inc is a preclinical stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma.